The Newsroom

Investigations  /  12.23.2020

Investigation of Genfit SA

You Have Legal Options

Genfit SA (GNFT) Misled Shareholders Regarding the Viability of its Lead Drug Candidate Elafibranor       

Genfit conducted its IPO on March 27, 2019, at the price of $20.32 per share.

At the time of the IPO, elafibranor was in a “pivotal” phase 3 clinical trial called “RESOLVE-IT,” which evaluated the efficacy and safety of elafibranor 120mg versus placebo in patients with nonalcoholic steatohepatitis (“NASH”) and fibrosis.  Genfit planned to use the data from the RESOLVE-IT study to support the Company’s new drug application to the FDA for elafibranor.  The Offering Documents supporting the IPO stated that Genfit had progressed to the phase 3 RESOLVE-IT study based on the positive results from Genfit’s phase 2b study concerning the efficacy elafibranor. Genfit stated that “The[] results provide strong and unequivocal evidence of the beneficial effects of [elafibranor] at 120 mg/d on the primary endpoint.” Further, the Offering Documents repeatedly stated that elafibranor was “well-positioned” for FDA approval.

On February 20, 2020, post-market, Genfit issued a press release announcing a delay in the release of topline interim results from the RESOLVE-IT study.  On this news, Genfit’s stock fell $1.05 per share, or 5.87% over two trading days.  Then, on May 11, 2020, during after-market hours, Genfit issued a press release announcing results from an interim analysis of the RESOLVE-IT phase 3 study of elafibranor, disclosing that “[e]lafibranor did not demonstrate a statistically significant effect on the primary endpoint of NASH resolution without worsening of fibrosis.”  On this news, Genfit’s ADS price fell 67.73%, or $14.90 per share, to close at $7.10 per share on May 12, 2020.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.


How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns